University of Florida’s Prometheon Pharma Launches Indiegogo Campaign for Needle-Free, Temperature Stable Insulin Patch Innovation
Prometheon Pharma, a research entity associated with the University of Florida, has recently initiated a substantial Indiegogo campaign with the aim of advancing the development of their revolutionary insulin patches. These innovative patches, created by former faculty members from UF and Harvard Medical School, led by Dr. Stephen Hsu, MD-PhD, have the potential to replace the painful and widespread practice of billions of needle injections annually.
The primary objective behind the creation of these needle-free patches is to enhance the quality of life for individuals worldwide suffering from Type I and Type II diabetes, as well as those who are pre-diabetic. In addition to their positive impact on patients, these patches also have the potential to alleviate the financial burden associated with healthcare costs.
The development and manufacturing of these patches are straightforward and cost-effective, making them easily accessible to a wide range of patients. Unlike other insulin delivery methods, these patches can be stored without the need for refrigeration, thus benefiting individuals residing in rural areas or facing financial constraints.
Prometheon Pharma's innovative patch offers continuous and reliable insulin delivery for up to 7 days, and users have the flexibility to replace it at their convenience, based on their lifestyle requirements. Another notable advantage of this patch over other delivery methods like oral, inhaled, or injected insulin is its relative ease of discontinuation when necessary.
Prometheon Pharma envisions making this groundbreaking patch available to patients by 2018, thereby revolutionizing insulin delivery and significantly improving the lives of individuals grappling with diabetes.
